HCA
SAGE

Harbor Capital Advisors’s Sage Therapeutics SAGE Stock Holding History

Harbor Capital Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-42,339
Closed -$230K – 1521
2024
Q4 		$230K Sell
42,339
-3,399
-7% -$20.8K 0.01% 641
2024
Q3 		$330K Buy
45,738
+8,166
+22% +$74.8K 0.01% 625
2024
Q2 		$408K Buy
37,572
+11,409
+44% +$146K 0.03% 565
2024
Q1 		$490K Sell
26,163
-2,322
-8% -$53.6K 0.06% 399
2023
Q4 		$617K Sell
28,485
-6,288
-18% -$125K 0.12% 211
2023
Q3 		$716K Buy
34,773
+13,720
+65% +$396K 0.15% 168
2023
Q2 		$990K Buy
+21,053
New +$1.05M 0.2% 131

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Harbor Capital Advisors's SAGE Position: Q1 2025 in Review

Harbor Capital Advisors sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 42,339 shares — an estimated $230K sold.

Harbor Capital Advisors first reported a position in SAGE in Q2 2023 and held it in 7 quarters. The position peaked at $990K in Q2 2023. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Harbor Capital Advisors reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Harbor Capital Advisors sold 42,339 Sage Therapeutics shares in Q1 2025, an estimated $230K.
  • Harbor Capital Advisors first reported a position in Sage Therapeutics in Q2 2023 and held it in 7 quarters.
  • Harbor Capital Advisors's Sage Therapeutics position peaked at $990K in Q2 2023.
  • 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Harbor Capital Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.